Curis targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timeline
Q4 2024 Management View CEO Jim Dentzer highlighted significant progress in their TakeAim Lymphoma study, which evaluates the combination of emavusertib and ibrutinib in primary central nervous system ...
Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ETCompany ParticipantsAdanna Alexander – IRPhillip Chan - ...
For more than 4 decades, Jonathan Smoots was a force in Wisconsin theater
The history of two great Wisconsin theaters began with Jonathan Smoots. As Theseus in "A Midsummer Night's Dream," Smoots ...